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Abstract Cardiovascular disease (CVD) is the leading cause of death in Argentina. Computer simulation
 models allow to extrapolate evidence to broader populations than the originally studied, over longer 
timeframes, and to compare different subpopulations. The Cardiovascular Disease Policy Model (CVDPM) is a 
computer simulation state transition model used to represent and project future CVD mortality and morbidity in the 
population 35 years-old and older. The objective of this study was to update Argentina’s version of the CVDPM. 
For this purpose, information from the 2010 National Census, the 2013 National Risk Factor Survey, CESCAS I 
study, and PrEViSTA study were used to update the dynamics of population size, demographics, and CVD risk 
factor distributions over time. Model projections were later calibrated by comparing them to actual data on CVD 
events and mortality in the year 2010 (baseline year) in Argentina. Country statistics for people 35 years-old and 
older reported for 2010 a total of 41 219 myocardial infarctions (MIs), 58 658 strokes, and 281 710 total deaths. 
The CVDPM, in turn, predicted 41 265 MIs (difference: 0.11%), 58 584 strokes (difference: 0.13%), and 280 707 
total deaths (difference: 0.36%) in the same population. In all cases, the final version of the model predicted the 
actual number of events with an accuracy superior to 99.5%, and could be used to forecast the changes in CVD 
incidence and mortality after the implementation of public policies.
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Resumen Actualización del modelo de políticas en enfermedad cardiovascular en Argentina. La en-
 fermedad cardiovascular (ECV) es la principal causa de muerte en Argentina. Los modelos de simula-
ción por computadora permiten extrapolar evidencia a poblaciones más amplias que las originalmente estudiadas, 
a lo largo de períodos prolongados, y comparar diferentes subpoblaciones. El Cardiovascular Disease Policy 
Model (CVDPM, por sus siglas en inglés) es un modelo de simulación utilizado para representar y proyectar la 
mortalidad y morbilidad por ECV en la población de 35 o más años. El objetivo de este trabajo fue actualizar la 
versión argentina del CVDPM. Para esto, se utilizó información del Censo Nacional 2010, la Encuesta Nacional 
de Factores de Riesgo 2013, el estudio CESCAS I, y el estudio PrEViSTA, para actualizar la dinámica del tama-
ño de la población, sus características demográficas, y la distribución de factores de riesgo cardiovasculares a 
lo largo del tiempo. Las proyecciones del modelo se calibraron comparándolas con información sobre eventos 
de ECV y mortalidad en el año 2010 (año de referencia) en Argentina. Las estadísticas argentinas informaron 
que en 2010 la población de 35 o más años sufrió un total de 41 219 infartos de miocardio (IM), 58 658 acci-
dentes cerebrovasculares y 281 710 muertes totales. El CVDPM predijo 41 265 IM (diferencia: 0.11%), 58 584 
accidentes cerebrovasculares (diferencia: 0.13%) y 280 707 muertes totales (diferencia: 0.36%). En todos los 
casos, la versión final del modelo predijo el número real de eventos cardiovasculares con una precisión superior 
al 99.5%, pudiendo ser utilizado para pronosticar cambios en la incidencia y mortalidad de ECV debidos de la 
implementación de políticas públicas.
 Palabras clave: modelos de simulación por computadora, enfermedad cardiovascular, Argentina, salud pública, 
políticas de salud 
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Non-communicable chronic diseases (NCDs) caused 
an estimated 39.5 million deaths in 2015, representing 
70% of all deaths worldwide1. Argentina is not an excep-
tion and cardiovascular diseases (CVD), the leading cause 
of death, were responsible for 28.9% of deaths in 20152. 
Clinical trials are still considered to be the gold standard for 
best practice evidence regarding cardiovascular disease, 
but due to the limited selected subset of individuals with 
whom these trials are conducted on, their applicability to 
evaluate health intervention effects on entire populations 
(i.e.: countries) has been questioned3. Computer simula-
tion models can assist with this problem, by scaling up 
evidence to a broader, more diverse population, and by 
extending intervention follow-up over longer timeframes3. 
They can also be used to compare different subpopula-
tions, or to compare effects of different interventions within 
the same population3. 
The Cardiovascular Disease Policy Model (CVDPM) is 
a computer simulation state transition model used over the 
past three decades to represent cardiovascular disease 
and to project future CVD mortality and morbidity in the 
United States4-9. In recent years, the CVD Policy Model 
structure has been adapted to represent other nations 
including Argentina, Mexico and China, using nation- spe-
cific demographic, risk factor, and hospital data as well 
as calibration to national measures of CVD incidence, 
prevalence and mortality10-12. 
Argentina’s version of this model was first developed 
in 2009 in collaboration with researchers from Argentina’s 
National Ministry of Health and from University of Buenos 
Aires and was used to project the potential impact of pub-
lic health policies aimed relating to salt consumption13,14 
tobacco smoke exposure15 and access to HMG CoA 
inhibitors at the primary care level16. 
The CVD Policy Model-Argentina (CVDPM-AR) has 
been recently updated, incorporating newly available 
epidemiologic and demographic data that better reflect 
contemporary CVD in Argentina. Here we describe the 
methodology used for updating the Argentinean version 
of the CVD Policy Model.
Materials and methods
The CVD Policy model (Fig. 1) is a computer simulation, state 
transition (Markov) model that estimates the prevalence and 
incidence of cardiovascular disease, as well as its associated 
mortality and direct health care costs, by using epidemiologi-
cal data of the population 35 years old and older (Fig.1)3. The 
model separates the population into those without prior coro-
nary heart disease (angina, myocardial infarction, and arrest) 
or stroke and those with prior CVD. The population without 
prior CVD is divided into cells defined by age, sex, and levels 
of CVD risk factors including systolic blood pressure (SBP), 
HDL and LDL cholesterols (HDL-c and LDL-c), smoking sta-
tus, diabetes status, and body mass index (BMI). In annual 
cycles, the model predicts the incidence of coronary heart 
disease, stroke, and death due to non-cardiovascular causes 
as a function of age, sex, and levels of CVD risk factors. In 
those who develop incident disease, the model character-
izes the incident event along with its sequelae for 30 days. 
In the population with a history of CVD, the model predicts 
subsequent cardiovascular events and procedures along with 
deaths from cardiovascular and non-cardiovascular causes as 
a function of age, sex, and prior CVD history. 
The CVD Policy Model–Argentina includes prevalence 
and mean values for the following CVD risk factors cutoffs, 
Fig. 1.– Cardiovascular disease policy model structure (Adapted from: Moran AE, Coxson 
P, Ferrante D, et al. 20153) 
CHD: coronary heart disease; LDL: low density lipoprotein cholesterol; HDL: high density 
lipoprotein cholesterol; BMI: body mass index; MI: myocardial infarction
The CVD Policy Model is a state-transition simulation model of CVD in adults. State 
transitions are numbered in the diagram: Transition 1 = remain in CVD-free state, with 
1-year cycle advancement of age and risk factor distribution; Transition 2 = incident CVD; 
Transition 3 = non-CVD death; Transitions 4 and 5 = survival or case fatality; Transition 
6 = survival with or without repeat CVD event in chronic CVD patients. 
Event
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stratified by sex and age decile (from 35-44 years old through 
85-94 years old): SBP: < 130; 130-139.9; ≥ 140 mmHg; LDL: 
< 100; 100-129.9; ≥ 130 mg/dl; HDL: <40; 40-59.9; ≥ 60 mg/
dl; smoking: active, passive, and non-smoking; diabetes: yes 
or no; BMI: < 25; 25-29.9; ≥ 30 kg/m2.
Risk factor interventions are modeled by changing the base 
level means of these risk factors.
Every adult alive in a given simulation year must be in a 
healthy or diseased state, and their risk is distinctively calcu-
lated according to their age, gender, and risk factors. Each 
simulation is run on an annual basis, with new 35-year-olds 
entering and those aging to 95 years exiting each cycle. As 
such, outcomes change over time according to dynamics of 
population size, demographics, and risk factor distributions 
over time4, 9.
A more detailed description of the model is available in 
previous publications3, 4.
An original version of Argentina’s CVD Policy Model was 
developed in 2009. Since then, new sources of information 
have become available: 
-The National Census conducted in 2010 was used to up-
date 2010 Argentina’s population, and to estimate the 35 years-
old people entering into the model each year up to 210017, 18.
-The 2013 National Risk Factor Survey was used to update 
age and sex-specific means and distributions for BMI, smok-
ing and diabetes19. 
-The CESCAS I study (Study for the detection and follow 
up of cardiovascular disease risk factors in the southern cone 
of Latin America), led by the South American Center of Excel-
lence for Cardiovascular Health, is an on-going observational 
prospective cohort designed to study cardiovascular disease 
prevalence and risk factors in Southern Latin America. This 
study provided information on age and sex specific means 
and prevalence for LDL, HDL and SBP20,21. 
-The Program for the epidemiological evaluation of stroke 
in Tandil (PrEViSTA) study reports local information on First-
Ever Stroke and Transient Ischemic Attack Incidence22.
After risk factors and demographic inputs are updated, the 
model is calibrated to reproduce contemporary cardiovascular 
disease morbidity and mortality data.  
Argentina’s population and risk factor distribution deter-
mined the rate of incident cardiovascular events (first events 
in the population without disease) with the multivariate effect of 
the risk factor distribution based on Cox proportional hazards 
models of data from the ongoing Framingham Heart Study and 
Framingham Offspring Cohort23, 24. We gathered local informa-
tion on the number of CVD events as well as CVD mortality 
for the year 2010 to use as standards for calibrating model 
transition rates (calibration targets). CVD, non-CVD, and total 
deaths (by age and gender) per year were estimated from Ar-
gentina’s National Vital Statistics for the year 2010. The actual 
total number of deaths attributable to coronary heart disease 
was estimated as a compound of both definite CHD deaths 
(codes I20-I25 of the International Classification of Diseases, 
10th Revision25) in health records plus a percentage of poorly 
defined deaths (named ‘garbage’ codes, already defined) that 
could be attributed to CHD deaths15, 26. Garbage codes are 
codes assigned to deaths that were supposedly misclassified 
as non-CHD deaths when they should have been coded as 
CHD deaths. The total number of deaths obtained was later 
corrected by a factor determined for countries with low quality 
of registry (such as Argentina) in the Global Burden of Dis-
ease initiative27. A similar method was then used to compare 
predicted and reported stroke deaths (using codes I60-I69).
In the absence of national data on the absolute total num-
ber of events for myocardial infarction (MI), arrest, or stroke, 
by age group and gender by year, calibration targets were 
determined using a combination of local studies (such as the 
SCAR study (Síndromes Coronarios Agudos en Argentina)28, 
a multicenter registry of CHD events in Argentina, and the 
already mentioned PrEViSTA Study) and US event rates  to 
infer event totals for calibration targets. 
Initial event rates in the population with prevalent car-
diovascular disease were assumed from the prior Argentina 
model version and were adjusted iteratively to match the 
2010 estimates of events, after subtracting the risk predicted 
incident events (events in the population without CVD). Then, 
for each of the events being analyzed, numbers obtained 
from calibration targets were compared to model estimations, 
calculating the ratio between both. These ratios were later 
applied to the model formulas, in order to bring its prediction 
closer to calibration targets. Then, a new simulation was run 
to check if the model fits real statistics. This iterative process 
was repeated until the model predictions adjusted to the 
calibration targets.
The baseline year for the current version of the CVDPM-
AR is 2010, and all model parameters were calibrated to meet 
targets estimated for 2010. 
Results
After the process of calibration, real and simulated total 
number of events and deaths due to MIs, arrest or strokes 
were compared, as well as total and non-CVD mortality. 
Table 1 presents the difference between model predic-
tions (estimated as described before) and national sta-
tistics following calibration. Total number of MIs, arrests 
and strokes were predicted with an accuracy superior to 
99.8%. 
In all cases, the final version of the model predicted 
the actual number of events with an accuracy superior 
to 99.5%.
The accuracy was also checked for the same outcomes 
but stratified by gender and age category; as an example, 
results for total number of MIs and mortality due to MIs 
can be seen in Table 2. 
Accuracy was once again higher than 99.5%.
Accuracy superior to 99% was also seen when com-
paring the predicted total number of strokes against the 
actual number of events, stratified by age and gender 
(data not shown).
Although the model is conceived to be calibrated in the 
baseline year (in this case, 2010), an all-cause mortality 
comparison was conducted for the years 2010-2015. 
Results are presented in Table 3 and Figure 2. Figure 
3 shows the same comparison but divided by CVD and 
Non-CVD mortality. 
Figure 2 shows that, although there is a gap between 
actual statistics and model predictions, the absolute differ-
ence in mortality rates (total mortality, CVD and Non-CVD 
mortality) is not bigger than 0.12.
Figure 3 shows that the slight overall increase in mortal-
ity rate in the model is due to an increase in CVD mortality. 
The decline in mortality seen in vital statistics is small but 
still many times greater than in the model and this may 
reflect real changes in risk.
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Figure 3 also shows that, while non-CVD mortality 
rate remains stable over the years, CVD mortality has 
a slight upward trend. It is important to understand 
that the model assumes that age-specific risk factor 
prevalence, and hence incidence of CVD and rates 
of non-CVD death, remain stable over the years in a 
baseline simulation.  The number of incident events in 
the model’s baseline (no intervention) predictions is 
only changing as a response to changes in the popu-
lation’s size and age distribution while incidence rates 
are steady. Prevalence of CVD is not controlled by the 
model and changes in response to changes in inci-
dence; but while the model intrinsically increases CVD 
incidence with age, Argentina data (as reported by the 
National Risk Factor Survey) suggest that CVD preva-
lence remains almost stable among people older than 
64 years old. The increase in incidence with a stable 
prevalence at the beginning is solved by the model by 
pushing up CVD prevalence in the first years after the 
baseline simulation, with the subsequent increase in 
CVD mortality. Nevertheless, the upward trend in CVD 
mortality is quite small (0.003% increase per year), and 
TABLE 1.– Comparison of overall outcomes between model predictions and actual 
statistics for 2010
 Real statistics Model predictions Difference
 (n) (n) (%)
Total number of MIs 41 219 41 265 0.11
Total number of arrests 10 122 10 132 0.10
Total number of strokes 58 658 58 584 – 0.13
MI deaths 5354 5359 0.09
Arrest deaths 10 122 10 132 0.10
Stroke deaths 18 241 18 253 0.07
Non-CVD deaths 231 396 230 391 – 0.43
Total deaths 281 710 280 707 – 0.36
MI: myocardial infarction; CVD: cardiovascular disease
TABLE 2.– Comparison of myocardial infarctions outcomes between model predictions and actual statistics for 2010, by 
age group and gender
 Total number of MIs MIs Mortality
  Actual Model Difference Actual Model Difference
  statistics predictions  statistics predictions
  (n) (n) (%) (n) (n) (%)
Men 35-44 1050 1048 – 0.19 41 41 0
 45-54 4559 4563 0.09 186 186 0
 55-64 9154 9166 0.13 642 643 0.16
 65-74 9782 9804 0.22 1260 1263 0.24
 75-84 5049 5059 0.20 1097 1099 0.18
 85-94 1553 1547 – 0.39 519 518 – 0.19
 Total 31 147 31 187 0.13 3745 3750 0.13
Women 35-44 274 274 0 11 11 0
 45-54 904 907 0.33 57 57 0
 55-64 2367 2363 – 0.17 232 232 0
 65-74 2550 2550 0 376 375 – 0.27
 75-84 2551 2562 0.43 532 534 0.38
 85-94 1427 1422 – 0.35 401 400 – 0.25
 Total 10 073 10 078 0.05 1609 1609 0
MI: myocardial infarction
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CVD prevalence reaches a steady state after a 10-year 
running (year 2020; data not shown).  
Additionally, the model’s age-adjusted overall mortality 
rates in Table 3 remain relatively stable and that means 
that model assumptions are properly working.
Discussion 
The updated version of the CVD Policy Model predicts 
accurately the occurrence of CVD events in Argentina in 
the year 2010, the baseline year, and could be used to 
TABLE 3.– Comparison of total mortality between model predictions and actual statistics
for the population 35-94 years old, 2010-2015
 Actual statistics Model predictions
 Total number Age Adjusted Total numbers Age Adjusted Difference in
 of deaths Rate**  of deaths Rate**  total number
 (n) (%) (n) (%) of events (%)
2010 281 710 1.677 280 707 1.671 – 0.36
2011 282 248 1.629 285 714 1.674 1.23
2012 282 749 1.598 290 913 1.677 2.89
2013 289 224 1.600 296 312 1.680 2.45
2014 288 942 1.566 301 576 1.683 4.37
2015 296 528 1.573 308 893 1.686 4.17
**Age adjusted rates are calculated as: [sum of (crude rates*2010 age specific population)] *100/total 2010 population
Fig. 2.– Comparison of total mortality age-adjusted rate, model predictions and actual 
statistics, 2010-2015
Fig. 3.– Comparison of cardiovascular disease and non-cardiovascular disease age-
adjusted mortality rates, model predictions and actual statistics, 2010-2015
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forecast the changes in CVD after the implementation of 
public policies. 
Modeling studies represent an important addition to 
traditional health effects and health economics studies, 
such as cost-effectiveness analysis, in which the impact 
of a specific intervention is usually evaluated through 
their effect in a single outcome in a limited population29. 
Modeling studies allow to expand both the population in 
question as well to analyze the effect of an intervention in 
more than one outcome, providing evidence-based sup-
port for health policy makers and government authorities29. 
Although other modelling studies have been used in 
Argentina30,31, the presented version of the CVDPM not 
only uses the most updated information, but also incor-
porates input data based on national samples as well as 
biological measures (instead of self-reported ones) for 
estimating mean values of CVD risk factors. The CVD 
Policy Model in particular has also been described by The 
Pan American Health Organization to evaluate the impact 
of an intervention on cardiovascular disease nationwide3.
We need to acknowledge some limitations. All model-
ling studies are as good as the integrity of their inputs. We 
used the best available data for Argentina to adapt the 
model, and in the case of some inputs we had to assume 
local or provincial data as nationally representative. 
Additionally, the coefficients used to estimate the rela-
tive risk of developing cardiovascular disease for each 
possible risk factor combination have been taken from the 
Framingham study, study conducted in a mostly Anglo-
Saxon population in of the United States32. Nevertheless, 
there is evidence that the associations between risk factors 
and events are the same across different populations33, 34.
Last, as it was mentioned, the CVDPM assumes that 
incidences and risk factor distributions remain stable. But 
CVD mortality seems to be lowering in Argentina; this 
could be due to multiple factors, such as a decrease in 
the prevalence of CVD risk factors or increased treatment 
effect (due to better diagnosis, more adherence, etc.). 
Regardless of the cause for this decrease, the model is 
intrinsically not able to predict changes in these factors 
over time. For future analysis, it is important to consider 
that, in this scenario, the total number of deaths may be 
overestimated.
Nevertheless, the CVDPM has shown to accurate 
predict events at the baseline year, and in case of over-
estimations a sensitivity analysis can be conducted, ad-
justing for the resulting ratios. Argentina has already used 
the CVDPM to inform national policies such as tobacco 
control, salt reduction intervention and lipid lowering pro-
grams13-16. This new version of the model can be used to 
continue applying an evidence-based approach on which 
to base health policy related decisions. 
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